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Introduction 
Synthetic cannabinoid receptor agonists (synthetic cannabinoids), such as ADB-CHMINACA, are a group 
of substances that mimic the effects of tetrahydrocannabinol (THC), which is a substance found in 
cannabis (1). THC is responsible for many of the psychoactive effects of cannabis which give that feeling 
of being 'stoned' (or 'high') (Gaoni et al, 1964;  Huestis et al., 2001; Pertwee, 2014). THC causes these 
effects by activating a receptor in the brain called the cannabinoid receptor type 1 (CB1 receptor) (Huestis 
et al., 2001;  Pertwee, 2005a). This receptor is part of a signalling system in the body called the 
endocannabinoid system, which helps regulate, among other things, behaviour, mood, pain, appetite, 
sleep, and the immune system (Pertwee, 2015) (2). Because synthetic cannabinoids activate the CB1 
receptor in a similar way to THC, some of their effects appear to be similar to cannabis. Most prominently, 
they are able to create a feeling of being                              
Synthetic cannabinoids were originally developed by scientists to study the endocannabinoid system, as 
well as provide insights into disease, and to help make new medicines (Pertwee, 2005a;  Pertwee, 2005b; 
Pertwee, 2015;  Reggio, 2009). From around 2006, they began to appear in Europe in products called 
 that were sold as  replacements to cannabis (Auwärter et al., 2009; EMCDDA, 2009; Jack, 
2009). In these products, synthetic cannabinoids had been mixed with plant (herbal) material which could 
then be smoked as cigarettes  (Auwärter et al., 2009 ; EMCDDA, 2009; EMCDDA, 2017a; Jack, 
2009). Such products have been referred to by a variety of names, including  smoking  
     and   Since 2008, almost 180 synthetic cannabinoids 
have been identified on the drug market in hundreds of different products. They are the largest group of 
substances that are monitored by the EMCDDA through the European Union Early Warning System on 
New Psychoactive Substances (EU Early Warning System) (EMCDDA, 2017b). 
In accordance with Article 5 of the Council Decision 2005/387/JHA on the information exchange, risk-
assessment and control of new psychoactive substances (3) on 25 April 2017, the EMCDDA and Europol 
launched the Joint Report procedure for N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-
1H-indazole-3-carboxamide (ADB-CHMINACA) on the basis of data reported by the Member States 
through the EU Early Warning System in accordance with Article 4 of the Council Decision. The 
information collection process for the Joint Report was completed in June 2017. The report was submitted 
to the Institutions of the European Union in July 2017 (EMCDDA, 2017c). In accordance with Article 6 of 
the Council Decision, on 14 September 2017, the Council of the European Union requested that a risk 
assessment on ADB-CHMINACA should be carried out by the extended Scientific Committee of the 
EMCDDA. 
In order to prepare for the risk assessment, and, to facilitate the risk assessment process, the EMCDDA 
is responsible for the collection and analysis of data on the substance to be assessed as well as drafting 
                                                     
(1) ( )-trans- 9-tetrahydrocannabinol. 
(2) The endocannabinoid system helps regulate a large number functions in the body. It consists of the cannabinoid CB1 and CB2 
receptors, the endocannabinoids (such as anandamide) which act as endogenous agonists for these receptors, and the processes 
responsible for endocannabinoid biosynthesis, cellular uptake, and metabolism. Important exogenous agonists for the cannabinoid 
receptors are ( )-trans- 9-tetrahydrocannabinol (THC) which is the major active substance in cannabis, and the synthetic 
cannabinoids found in legal high-type smoking mixtures. Data from laboratory studies suggests that the endocannabinoid system 
plays an important protective role. For example, in response to some diseases the body increases the amount of endocannabinoids 
it produces which can reduce unwanted symptoms or slow disease progression (Pertwee, 2005a;  Pertwee, 2005b; Pertwee, 2015). 
(3) OJ L 127, 20.5.2005, p. 32.  
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a technical report. This technical report has been prepared for the risk assessment of ADB-CHMINACA 
that will be held at the EMCDDA premises in Lisbon on Tuesday 7 November 2017. 
Some of the sections in this report were prepared under EMCDDA contracts (ref. CT.17.SAT.0084.1.0 
and CT.17.SAT.0110.1.0) 
Data sources 
The information in this technical report is derived from: 
 data reported by the Member States, Turkey and Norway to the EMCDDA and Europol in 
accordance with the Council Decision (EMCDDA, 2017c); and,  
 data collected through systematic searches of open source information, including the scientific 
and medical literature, patents, official reports, grey literature, Internet drug discussion forums 
and related websites, and online vendors selling ADB-CHMINACA. 
Search strategy  
Literature searches used both chemical structure and text queries in online databases; searches were 
conducted in early October 2017. The retrieved publications were then reviewed for additional relevant 
references (snowballing technique). 
Chemical structure-based searches were done in SciFinder® (American Chemical Society, Chemical 
Abstract Service) and Reaxys® (Elsevier) databases using both the exact structure of ADB-CHMINACA 
and a similarity search. Structural and text-based searches in the SureChEMBL patent database retrieved 
no relevant hits. 
Textual searches were conducted online in PubMed (National Center for Biotechnology Information), Web 
of  (Thomson Reuters), and in popular English-language drug forums. The search terms used 
were: ADB-CHMINACA  and - . 
The REACH registered substances database hosted by the European Chemicals Agency (ECHA) was 
searched using the CAS registry numbers listed below. The searches returned no hits. 
Cursory, though repeated, inspections of Internet forums covered Bluelight, Drugs-forum, 
ecstasydata.org, Erowid, Eve&Rave, Reddit and The Vespiary. 
Additionally, the scientific networks of the authors were contacted to obtain information. 
Note 
It is important to note that when interpreting the information on self-reported user experiences in this 
report, it is not possible to confirm the specific substance(s) that have been claimed to be used; similarly it 
is also not possible to confirm the strength, purity, dose/amount, etc., used. Moreover, the actual 
composition of the substance/product may differ over time and different geographical areas. In addition, 
the information provided on user websites may not necessarily be representative of other users of ADB-
CHMINACA and should be regarded as illustrative only. In general, given the difficulties of collecting 
accurate self-reported data, it should be interpreted with caution. 
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Section A. Physical, chemical, pharmaceutical and pharmacological information 
A1. Physical, chemical, and pharmaceutical information 
A1.1. Physical and chemical description 
Chemical description and names 
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide, also known 
as ADB-CHMINACA and MAB-CHMINACA (Figure 1), is a synthetic cannabinoid receptor agonist 
(synthetic cannabinoid). The common name for the substance is derived after its structural features (7): a 
dimethylaminobutanone linked group (ADB), a cyclohexylmethyl tail (CHM), an indazole core (INA) and a 
carboxamide linker (CA).  
ADB-CHMINACA contains a stereogenic centre and therefore two possible enantiomers may exist, (R)- 
and (S)-ADB-CHMINACA. (S)-ADB-CHMINACA was originally described in a patent application by Pfizer 
Inc. and published in 2009 (compound 13) (Buchler et al., 2009). Based on the literature and the most 
likely precursors to be used, an (S)-configuration of the stereocentre could be expected. However, there 
is no representative information on the enantiomeric composition of the samples of ADB-CHMINACA 
detected within the European Union. 
ADB-CHMINACA was first reported to the EMCDDA in 2014.  
Five synthetic cannabinoids have been recently controlled under Schedule II of the United Nations 
Convention on Psychotropic Substances, 1971: JWH-018 (8), AM-2201 (9), MDMB-CHMICA (10), 5F-
APINACA (5F-AKB-48) (11) and XLR-11 (12). Other synthetic cannabinoids, including the valinamide 
analogue of ADB-CHMINACA called AB-CHMINACA (13) (EMCDDA, 2017d), 5F-MDMB-PINACA (5F-
ADB) (14) (EMCDDA, 2017e), and CUMYL-4CN-BINACA (15) (EMCDDA, 2017f) have also been the 
subjects of EMCDDA Europol Joint Reports. 
 
 
 
                                                     
(7) Different naming systems exist and are used for applying short/code names to synthetic cannabinoids. 
http://www.emcdda.europa.eu/topics/pods/synthetic-cannabinoids 
(8) JWH-018: (Naphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone.  
(9) AM-2201: [1-(5-Fluoropentyl)-1H-indole-3-yl](naphthalen-1-yl)methanone.  
(10) MDMB-CHMICA: Methyl (2S)-2-{[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate.  
(11) 5F-APINACA: N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide. 
(12) XLR-11: [1-(5-Fluoropentyl)-1H-indole-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone.  
(13) AB-CHMINACA: N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide.  
(14) 5F-MDMB-PINACA (5F-ADB): Methyl (2S)-2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate. 
(15) CUMYL-4CN-BINACA: 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide.  
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C21H30N4O2 C20H28N4O2 
370.50 g/mol 356.47 g/mol 
Figure 1. The molecular structure, molecular formula and molecular mass of 
ADB-CHMINACA (left) and AB-CHMINACA (right). 
 
Names and other identifiers 
Systematic International Union of Pure and Applied Chemistry (IUPAC) name:  
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide.  
Chemical Abstract name:  
1H-Indazole-3-carboxamide, N-[(1S)-1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)- 
1H-Indazole-3-carboxamide, N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)- 
Other names:  
N-[1-(Aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide; 
N-(1-Carbamoyl-2,2-dimethyl-propyl)-1-(cyclohexylmethyl)indazole-3-carboxamide; 
N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide; 
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide; 
N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide 
((S)-enantiomer); 
N-[(1S)-1-(Aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide 
((S)-enantiomer); 
N -[1-(Cyclohexylmethyl)-1H-indazole-3-yl-carbonyl]-3-methyl-L-valinamide. 
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Chemical Abstract Service Registry Numbers (CAS RNs) (16) 
1863065-92-2: racemate 
1185887-13-1: ((S)-enantiomer) 
PubChem SID:  
68894304 ((S)-enantiomer) (17) 
IUPAC International Chemical Identifier Key (InCHI Key) (18):  
ZWCCSIUBHCZKOY-UHFFFAOYSA-N (racemate) 
ZWCCSIUBHCZKOY-GOSISDBHSA-N ((S)-enantiomer);  
SMILES (19): 
CC(C)(C)C(C(=O)N)NC(=O)c1c2ccccc2n(n1)CC3CCCCC3 (racemate); 
CC(C)(C)[C@H](NC(=O)c1nn(CC2CCCCC2)c3ccccc13)C(N)=O ((S)-enantiomer) 
Common names: ADB-CHMINACA, MAB-CHMINACA. 
Street names:  
ADB-CHMINACA; MAB-CHMINACA; Spice ; K2 , legal weed , synthetic cannabis , herbal incense .  
Manufacturers of herbal smoking mixtures frequently change the synthetic cannabinoids in the products, 
which means that product names are not a reliable source of information regarding the actual substances 
that are present (e.g. Frinculescu et al., 2017, Moosmann et al., 2015). 
Identification and analytical profile 
Physical description  
ADB-CHMINACA has been described as a white powder (SWGDRUG, 2016), crystalline solid (Cayman 
Chemical Company, 2014) and neat solid (Cayman Chemical Company, 2016). It is soluble in 
dichloromethane (DCM), methanol (MeOH) and is poorly soluble in water (Slovenian National Forensic 
Laboratory, 2016). Its solubility has also been described as follows: ~0.5 mg/mL in 1:1 dimethyl 
sulfoxide:phosphate-buffered saline (pH 7.2); ~1 mg/mL in ethanol; ~10 mg/ml in dimethyl sulfoxide and 
~5 mg/mL in N,N-dimethylformamide (Cayman Chemical Company, 2014). The reported melting point for 
                                                     
(16) The Chemical Abstract Service Registry Number (CAS RN) is a unique numeric identifier assigned by the Chemical Abstract 
Service Division of the American Chemical Society to a specific, single chemical substance. 
(17) https://pubchem.ncbi.nlm.nih.gov/compound/68894304 
(18) InChI Key is a unique, non-proprietary structural identifier of chemical substances useful in electronic sources. 
(19) The simplified molecular-input line-entry system (SMILES) is a unique, non-proprietary structural identifier of chemical 
substances useful in electronic sources. 
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ADB-CHMINACA is 141.5 °C (SWGDRUG, 2016). ADB-CHMINACA has been typically seized in herbal  
material and in powder form. A more detailed description of seizures and collected samples reported to 
the EMCDDA can be found in Section C. 
ADB-CHMINACA carries one asymmetric carbon atom. Based on the patent literature and the most likely 
precursors, an (S)-configuration of the stereocentre can be assumed, possibly due to the use of the 
reagent L-tert-leucinamide in its preparation. The biological evaluation of the compounds described in the 
Pfizer patents exclusively report on compounds with the (S)-configuration, and, since data on the (R)-form 
were not included, it is not known how the stereochemistry may affect its biological activity, including 
activity on the cannabinoid receptors. The absolute configuration of the structurally similar synthetic 
cannabinoid MDMB-CHMICA has recently been described in the literature which confirmed the (S)-
configuration in samples from the drug market (including a seizure of a powder as well as   type 
herbal smoking mixtures) (Andernach et al., 2016). 
Chemical stability and typical reactions 
For long-term storage it is recommended that ADB-CHMINACA, supplied as a solid, is stored at -20 °C 
(Cayman Chemical Company, 2016). In the case of the AB-CHMINACA analogue, it has been reported 
that hydrolysis of the terminal amide function can occur as a consequence of smoking but also following 
deposition on human hair (Franz et al., 2016a), which suggested that this degradation was not reserved 
solely for a metabolic transformation. It seems conceivable that a similar phenomenon, i.e. formation of 
the carboxylic acid derivative, might be observable for ADB-CHMINACA as well. A study assessing the 
freeze/thaw stability (3 cycles, at least 20 h freezing and one hour thawing at room temperature) in serum 
revealed that ADB-CHMINACA degraded only 3.6%. A long-term storage stability study in serum showed 
that ADB-CHMINACA was stable for at least 31 days at -20 °C (decomposition occurred at/after 105 
days), 31 days at 4 °C (but unstable at 105 days), and over 315 days at room temperature (stability 
criterion: measured degradation below 20%) (Hess et al., 2016).  
Analytical profile 
Analytical data for ADB-CHMINACA is abundantly available and several studies have explored its 
characterization and detection in various matrices such as herbal mixtures , powders and biofluids (Table 
1). The analysis of biological samples requires sensitive methods of analysis, e.g. liquid chromatography 
coupled to tandem mass spectrometry approaches, especially when blood-derived samples are involved. 
The detection of synthetic cannabinoid metabolites is a frequently chosen method for urine analysis 
although there are examples where the parent synthetic cannabinoid species has been targeted 
quantitative analysis in this particular matrix (Minakata et al., 2017).  
Table 1. Studies associated with the detection and chemical analysis of ADB-CHMINACA (amongst other 
substances) published in the scientific literature. 
Techniques a Comment  Reference 
1H-NMR, API-MS Synthesis and characterization. Buchler et al. (2009) 
GC-MS; LC-MS/MS Intoxication cases and analysis of 
biofluids.  
Franz et al. (2015)  
LC-QqQ-MS/MS Detection of ADB-CHMINACA in 
biofluids and tissue samples 
obtained from a fatal intoxication. 
Hasegawa et al. (2015a) 
LC-QTOF-MS Detection of ADB-CHMINACA in Kasper et al. (2015) 
10 
serum samples. 
Not reported. Detection of ADB-CHMINACA in 
biofluids. 
Trecki et al. (2015) 
GC-MS, LC-QqQ-MS/MS Detection of ADB-CHMINACA in 
  
Wurita et al. (2015) 
LC-QqQ-MS/MS Analysis of blood samples obtained 
from two intoxication cases. 
Adamowicz and Gieron (2016) 
GC-MS, LC-TOF-MS Characterization of reference 
material. 
Akamatsu and Yoshida (2016) 
Not reported Detection of ADB-CHMINACA in 
fatal intoxication cases. 
Babel et al. (2016)  
LC-QTOF-MS Blood analysis involving fatal 
intoxication. 
Bottei et al. (2016) 
Immunoanalysis, LC-MS/MS Evaluation of immunoassays using 
authentic urine samples.  
Franz et al. (2016b) 
LC-MS/MS Analysis of urine and serum samples 
obtained from an intoxication case. 
Hermanns-Clausen et al. (2016) 
LC-QTRAP-MS/MS Stability studies in human plasma. Hess et al. (2016) 
GC-MS Identification in samples obtained 
from dealer.  
Kaizaki-Mitsumoto et al. (2016) 
LC-MS Analysis of serum samples collected 
from 11 acute intoxication cases. 
Katz et al. (2016) 
GC-TOF-MS, GC-EI-MS, NMR, LC-
MS/MS, IR, UV 
Identification in   
collected from Internet retailers. 
Langer et al. (2016) 
GC-MS, LC-TOF-MS, ATR-FTIR, 
GC-MS, GC-IR, IC 
Characterization of test purchase 
sample. 
Slovenian National Forensic 
Laboratory (2016) 
Melting point, 1H-NMR, GC-MS, 
ATR-FTIR 
Characterization of reference 
material. 
SWGDRUG (2016) 
LC-Q-Orbitrap-MS/MS Metabolism study using ten-donor-
pooled cryopreserved human 
hepatocytes.  
Carlier et al. (2017a) 
LC-MS/MS Analysis of human urine sample 
obtained from autopsy and 
quantitation of two metabolites. 
Hasegawa et al. (2017) 
LC-MS/MS Analysis of serum and urine samples 
collected from intoxication cases.  
Hermanns-Clausen et al. (2017) 
Not reported Review of cases associated with 
motor vehicle collisions in Japan 
between 2012 and 2014. 
Kaneko (2017) 
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GC-MS Analysis of blood and urine 
specimen involved in intoxications 
between July 2015 and July 2016.  
Mazer-Amirshahi et al. (2017) 
LC-QTRAP-MS/MS Analysis of urine samples obtained 
from autopsies.  
Minakata et al. (2017) 
LC-MS/MS Detection in biofluids associated with 
intoxication cases. 
Moosmann et al. (2017) 
GC-MS Analysis of products obtained from 
Internet retailers. 
Müller et al. (2017) 
LC-QqQ-MS/MS Analysis of blood samples collected 
between March and December 2015. 
Tynon et al. (2017) 
LC-MS/MS, CB receptor activation 
assay using NanoLuc luciferase 
Receptor assay development and 
analysis of authentic urine samples. 
Cannaert et al. (2017) 
a NMR: nuclear magnetic resonance spectroscopy; API: atmospheric pressure ionization; LC: liquid chromatography 
(various forms); GC: gas chromatography; MS: mass spectrometry; MS/MS: tandem mass spectrometry; QqQ: triple 
quadrupole; QTOF: quadrupole time-of-flight; EI: electron ionization; IR: infrared spectroscopy; UV: ultraviolet 
spectroscopy; ATR: attenuated total reflectance; FT: Fourier transform; IC: ion chromatography. 
Methods and chemical precursors used for the manufacture 
Synthesis 
Information about the methods used for the synthesis of the ADB-CHMINACA that has been detected on 
the drug market in Europe has not been reported to the EMCDDA. However, it seems likely that the 
methods described in the work published by Pfizer Inc. (compound 13) might have been used for the 
manufacturing of this substance destined for the drug market. The specific conditions for the ADB-
CHMINACA synthesis have not been disclosed, but the preparation of the synthetic cannabinoids 
covered followed the scheme shown in Figure 2. The final reaction step (c) involves the coupling of the 
acid intermediate (3) with L-tert-leucinamide, which yields the (S)-enantiomer of ADB-CHMINACA as 
disclosed by Buchler et al. (2009). Although not explicitly mentioned in the work published by these 
authors, employing D-tert-leucinamide or the D,L-racemate should theoretically give the (R)- and racemic 
form of ADB-CHMINACA. L-tert-Leucinamide can be prepared from L-tert-leucine (Banister et al., 2015, 
Buchler et al., 2009). If this intermediate were more readily available and less expensive than D-tert-
leucine then one would expect this to have an impact on the manufacturing process, thus, potentially 
favouring the production of the (S)-form as originally disclosed by Pfizer Inc. A recent investigation on the 
isolation from another tert-leucine derived synthetic cannabinoid (MDMB-CHMICA) used in herbal 
smoking mixtures revealed that the compound was indeed showing the (S)-configuration (Andernach et 
al., 2016).  
 
Figure 2. Synthesis route for ADB-CHMINACA ((S)-enantiomer) starting from methyl 1H-indazole-3-carboxylate 
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(which might also be prepared) (1). Reagents: (a) base (e.g. sodium hydride, potassium tert-butoxide, sodium 
hexamethyldisilazide, or potassium carbonate) and (X-methyl)cyclohexane (X = leaving group; e.g. halogen, 
mesilate, or tosylate) provide (2); (b) saponification with aqueous base (e.g. sodium hydroxide, potassium hydroxide, 
or lithium hydroxide) yields (3); (c) amide bond coupling with L-tert-leucinamide using a carboxyl group activating 
reagent provides (4) (e.g. N,N´-dicyclohexylcarbodiimide (DCC) or 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide 
(EDC), either alone or in combination with 1-hydroxybenzotriazole (HOBt) and uronium reagents such as O-(7-
azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), O-(benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU), or O-(benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
tetrafluoroborate (TBTU)). The two nitrogen atoms found in the indazole ring of ADB-CHMINACA (4) have been 
numbered indicate the site of alkylation (20).  
Commercially available domestic or industrial products which could be used for synthesis may contain 
potentially toxic substances, including heavy metals and organic solvents. Use of such products as 
reagents may result in serious toxic effects if the resultant impure product is consumed. The herbal 
material which is used as a basis for the smoking mixtures may contain toxicologically relevant 
substances like e.g. pesticides potentially present in the plant material as well. 
Typical impurities encountered in seized and collected samples 
There are no quantitative data available on the impurities detected in seized and collected samples 
reported to the EMCDDA. However, the analysis of an ADB-CHMINACA sample purchased from an 
Internet retailer was reported to contain an unidentified impurity (Slovenian National Forensic Laboratory, 
2016). It was commented that the impurity might have been related to an impurity detected in a test 
purchased APP-CHMINACA product (21). In this case, the reported impurity was characterized by the 
presence of a second cyclohexylmethyl substituent on the molecule (Slovenian National Forensic 
Laboratory, 2015), which might be consistent with dialkylation. Although not documented, the N1-
alkylation can be carried out on the indazolyl tert-leucinamide derivative as the last step under conditions 
described for serotonin receptor antagonists (Furlotti et al., 2012; Schaus et al., 1998) and, recently, for 
the preparation of a metabolite of the synthetic cannabinoid receptor agonist AKB-48 (Wallgren et al., 
2017). In addition, it has been reported that the preparation of various indazole-based synthetic 
cannabinoids can result in the formation of another regioisomer that is alkylated at the N2-position, which 
was shown to depend on the base used for the alkylation reaction (Buchler et al., 2009, Longworth et al., 
2016). However, reports on the detection of these synthesis by-products could not be identified.  
A1.2. Physical/pharmaceutical form  
Data from seizures and collected samples reported to the EMCDDA have revealed that ADB-CHMINACA 
has typically been detected in plant/herbal material (herbal smoking mixtures) and powders. A small 
number of other forms have also been encountered, which included blotters,   
containing other synthetic cannabinoids and substances such as caffeine, a  mixed with another 
synthetic cannabinoid (MDMB-CHMICA ) and a  containing various additional synthetic 
                                                     
(20) The detection of a  contaminant in ADB-CHMINACA samples (Slovenian National Forensic Laboratory, 
2016; see also next paragraph) suggests an alternative production method in which a cyclohexylmethyl derivative alkylating agent is 
reacted with the N-indazolyl-tert-leucinamide (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-indazole-3-carboxamide). 
Overalkylation could, in theory, take place not only at the indazole N-atom but also at the nitrogen  or even of the oxygen  atom of 
the amide group(s). 
(21) APP-CHMINACA (PX3): N-[(2S)-1-Amino-1-oxo-3-phenylpropan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide.  
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cannabinoids apart from ADB-CHMINACA (AB-FUBINACA (22), 5F-ADB-PINACA (23) and FUB- 
APINACA (24)) (EMCDDA, 2017c). The Pfizer Inc. patent also refers to the use of synthetic cannabinoids 
in a range of pharmaceutical compositions depending on the methods used for administration (Buchler et 
al., 2009).  
For the production of smoking mixtures, the substance is dissolved in an organic solvent (e.g. acetone) 
and applied to the plant material such as damiana (Turnera diffusa) or marshmallow (Althaea 
officinalis) either via spraying or soaking and subsequent evaporation of the solvent (EMCDDA, 2017a). 
A1.3. Route of administration and dosage  
The most common route of administration for synthetic cannabinoids is smoking ready-to-use or self-
prepared   as a joint or utilizing a vaporizer,  or pipe. Because these ready-to-use 
products rarely state the ingredients, most users may be unaware that they are using ADB-CHMINACA. 
In addition, and, unknown to users, the concentrations of synthetic cannabinoids found in smoking 
mixtures can vary dramatically, which may range from low mg/g to hundreds of mg/g, depending on the 
potency of the substance and manufacturing practices involved (e.g. Ernst et al., 2017; Frinculescu et al., 
2017; Langer et al., 2014; Langer et al., 2016; Moosmann et al., 2015) (Section D3.4). 
Dosage 
Limited information is available regarding the dose and the dose regimens of ADB-CHMINACA. User 
reports specifically about ADB-CHMINACA were not particularly revealing and it is not possible to discern 
the  dosages administered by users.  
One website lists the following dosage information for the valinamide analogue AB-CHMINACA 
(smoking):  50 100   100 250   250 400   400+  (Tripsit, 
2017). As already highlighted in the introduction, the assessment of such reports is problematic not least 
because users cannot confirm the actual substance used. Information about the extent to which this can 
be translated to ADB-CHMINACA could not be identified.  
A2. Pharmacology, including pharmacodynamics and pharmacokinetics  
Pharmacologically, ADB-CHMINACA is a cannabinoid receptor agonist. 
Pharmacodynamics 
The limited available data suggest that ADB-CHMINACA binds to and activates the cannabinoid CB1 
receptor. For example, ADB-CHMINACA was reported to bind to the human CB1 receptor expressed and 
prepared from human embryonic kidney cells with a Ki value of 0.289 nM (radioligand [3H]CP-55,940) (25), 
which compared to a Ki value of 0.519 nM for AB-CHMINACA (Buchler et al., 2009). The United States 
Drug Enforcement Administration reported a Ki value of 0.49 nM (experimental details not provided 
                                                     
(22) AB-FUBINACA: N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide. 
(23) 5F-ADB-PINACA: N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(5-fluoropentyl)-1H-indazole-3-carboxamide. 
(24) FUB-APINACA: N-(Adamantan-1-yl)-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide. 
(25) Ki represents the equilibrium inhibition constant for the test drug displacing the radioligand.  
14 
including information about the absolute configuration) (US DEA, 2014). When using the in vitro 
[35  binding assay (receptors expressed in Chinese hamster ovary cells), the EC50 value reported 
for ADB-CHMINACA was 0.620 nM (26), which suggests that this compound was a potent agonist 
although efficacy information was not reported. In comparison, the EC50 value reported for AB-
CHMINACA was 2.55 nM, indicating that ADB-CHMINACA was 4 times more potent than its valinamide 
counterpart (Buchler et al., 2009). A comparison between efficacies could not be made since these data 
were not reported. Functional activity studies using the same assay (details not reported) produced via 
the DEA-VA Interagency Agreement revealed an EC50 value of 0.214 nM (US DEA, 2014), similarly 
indicating that ADB-CHMINACA displays potency values in the sub-nanogram range. The reason as to 
why the patent published by Pfizer only explicitly featured the (S)-enantiomers (Buchler et al., 2009) has 
not been disclosed and it is not known whether the (R)-forms showed reduced biological activity (27). A 
recent study exploring the differences in functional activity (in vitro [35  binding assay) between 
five pairs of enantiomeric synthetic cannabinoids, namely AB-FUBINACA (2-fluorobenzyl isomer) (28), 
APP-CHMINACA (29), EMB-FUBINACA (30), 5F-EMB-PINACA, and MDMB-FUBICA (31), revealed that 
agonist activity at CB1 and CB2 receptors was retained in most of the (R)-enantiomers. A drop in potency 
was determined at CB1 but not always at the CB2 receptor. (R)-MDMB-FUBICA, however, was reported to 
have lost activity at the CB1 receptor (Doi et al., 2017). 
A recent study reported CB1/2 receptor EC50 values and activation efficiency data (via -arrestin 2 
recruitment), for a range of synthetic cannabinoids, including ADB-CHMINACA, and some hydroxylated 
urinary metabolites (Cannaert et al., 2017). In the case of ADB-CHMINACA, the respective EC50 values 
for the CB1 and CB2 receptor are 1.49 and 2.2 nM in this assay system. For JWH-018, which was one of 
the comparative drugs, the respective EC50 values for the CB1 and CB2 receptor were 23.9 and 6.8 nM, 
which suggested a 16-fold (CB1) and 3.1-fold (CB2) increase in potency compared to JWH-018. CB1/2-
mediated receptor activation data relative to JWH-018 (concentration of all test drugs 10 M) have also 
been investigated and summarized in Table 2 below, which revealed that ADB-CHMINACA was almost 
two times more effective than JWH-018 in activating the CB1 receptor. In comparison, CB2 receptor 
activation induced by ADB-CHMINACA was observed to reach the 82% level. 4-HO-AB-CHMINACA, one 
of the three metabolites investigated, was capable of inducing a slightly stronger CB1 receptor activation 
than JWH-018. The extent to which these metabolites contribute to psychoactive effects in vivo remains 
to be investigated. The effect of ADB-CHMINACA on pharmacological or biochemical targets other than 
the cannabinoid receptors has not been studied. 
Table 2. Receptor activation efficacy of ADB-CHMINACA and three of its metabolites ± SEM (number of replicates) 
relative to JWH-018 (modified from Canneart et al., 2017). 
                                                     
(26) EC50 represents the half maximal effective concentration.  
(27) The chiral amino acid precursor (S)-L-tert-Leucine is widely used for the manufacture of antiviral medicines (such as the HIV 
protease inhibitor atanazavir or the hepatitis C virus protease inhibitors asunaprevir, bocepvir, grazoprevir, faldaprevir, narlaprevir, 
telaprevir, vaniprevir). (S)-L-tert-Leucine is produced mainly in China in large, multi-ton quantities. This may explain the choice of 
this precursor for the synthesis of ADB-CHMINACA and other related synthetic cannabinoids including MDMB-CHMICA (EMCDDA, 
2017g) that have been reported to the EMCDDA through the EU Early Warning System 
(28) AB-FUBINACA (2-fluorobenzyl isomer): N-[1-Amino-3-methyl-1-oxobutan-2-yl]-1-[(2-fluorophenyl)methyl]-1H-indazole-3-
carboxamide. 
(29) APP-CHMINACA (PX3): N-[1-Amino-1-oxo-3-phenylpropan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide.  
(30) EMB-FUBINACA: Ethyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate. 
(31) MDMB-FUBICA: Methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indole-3-carbonyl}amino)-3,3-dimethylbutanoate. 
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Drug/metabolite Relative efficacy of CB1 activation 
at 10  
Relative efficacy of CB2 activation 
at 10  
JWH-018 100 ± 4.6 (4) 100 ± 19.9 (4) 
ADB-CHMINACA 194.3 ± 13.7 (4) 82.1 ± 10.6 (4) 
4-OH-ADB-CHMINACA (M1) (32) 110.5 ± 6.0 (4) 62.1 ± 8.67 (4) 
tert-Leucine-ADB-CHMINACA (M2) 
(33) 
56.9 ± 4.3 (4) 85.7 ± 12.8 (4) 
tert-Leucine-4-OH-ADB-CHMINACA 
(M3) (34) 
36.4 ± 4.3 (4) 70.9 ± 11.6 (4) 
Animal studies 
Information derived from animal studies could not be identified, although it seems conceivable that ADB-
CHMINACA would display activity in assays that probe for 9-THC-like properties such as drug 
discrimination or mouse tetrad tests similar to what has been demonstrated with AB-CHMINACA. In the 
tetrad test battery that evaluates drug-induced changes in spontaneous motor activity, antinociception, 
ring immobility, and body temperature, AB-CHMINACA (i.p. administration) was shown to be 11- to 58 
times more potent than 9-THC (Wiley et al., 2015).  
Pharmacokinetics 
An incubation study with ten-donor-pooled cryopreserved human hepatocytes (10  ADB- 
CHMINACA, 3 h) identified ten major phase I metabolites (Figure 3). Key reactions included oxidation of 
the cyclohexylmethyl substituent into hydroxylated (A4 A6, A8 and A9) or ketone (A7) species; tert-butyl 
hydroxylation (A10), and dihydroxylation (A1, A2, A3) also occurred to some extent. Interestingly, 
transformations at the indazole core, the carboxamide linker, or the dimethylbutanamide side chain 
(including hydrolysis of the terminal amide) were not observed (Carlier et al., 2017a). Correspondingly, 
the ADB-CHMINACA species hydroxylated at the cyclohexylmethyl substituent have been recommended 
as compound-specific analytical targets.  
                                                     
(32) 4-OH-ADB-CHMINACA (M1): N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-hydroxycyclohexyl)methyl]-1H-indazole-3-
carboxamide. 
(33) tert-Leucine-ADB-CHMINACA (M2): (2S)-2-{[1-(Cyclohexylmethyl)-1H-indazole-3-carbonyl]amino]}-3,3-dimethylbutanoic acid. 
(34) tert-Leucine-4-OH-ADB-CHMINACA (M3): (2S)-2-({1-[(4-Hydroxycyclohexyl)methyl]-1H-indazole-3-carbonyl}amino)-3,3-
dimethylbutanoic acid. 
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Figure 3. Proposed metabolic pathway of ADB-CHMINACA. Dominant pathways are indicated by double arrows 
(Carlier et al., 2017a). 
 
Interestingly, no phase II reaction products have been observed and amide hydrolysis resulting in the 
formation of the carboxylic function has also not been detected under the conditions studied, which 
deviated from incubation studies carried out with the L-tert-leucinamide derivative ADB-FUBINACA (35) 
where more extensive biotransformations (23 metabolites) were observed (Carlier et al., 2017b). In the 
case of ADB-FUBINACA, the cyclohexylmethyl substituent found in ADB-CHMINACA is replaced by a (4-
fluorophenyl)methyl moiety. An investigation into the quantitation of ADB-CHMINACA metabolites in 
authentic urine specimen collected from an autopsy case performed in 2014 has recently been reported. 
Two hydroxylated metabolites were investigated, namely the (4-hydroxycyclohexyl)methyl derivative of 
ADB-CHMINACA (2.17 ng/mL) and its tert-butyl hydroxylated derivative (10.2 ng/mL) (Hasegawa et al., 
2017), which would reflect the metabolites A4 and A2 reported by Carlier et al. (Carlier et al., 2017a) 
(Figure 3). The parent molecule ADB-CHMINACA has been shown to be still detectable in authentic urine 
samples at a concentration of 229 pg/mL (Minakata et al., 2017).  
A number of ADB-CHMINACA metabolites have been detected in authentic human urine samples 
(unpublished observations): the (4-hydroxycyclohexyl)methyl metabolite (M1) (36) and its regioisomeric 
alcohol (hydroxylation site is not specified); the hydrolysed terminal amide species (M2), and the 4-
hydroxycyclohexyl)methyl analogue of the hydrolysed terminal amide (M3) and four M3 isomers (Table 2) 
(Cannaert et al., 2017). 
Additional information on the pharmacokinetic properties of ADB-CHMINACA could not be identified. 
Relevant user reports on the Internet about ADB-  effect profile are limited.  
                                                     
(35) ADB-FUBINACA: N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide.  
(36) The designations M1 M3 were based on the reference materials offered by the Chemical Company, Ann Arbor, M, USA. 
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Based on an in vitro assay evaluating the changes of membrane potentials following G-protein activation, 
it was found that the transition from a L-valinamide to L-tert-leucinamide moiety led to an increase in 
potency at the CB1 receptor, at least in some cases (Banister et al., 2016, Banister et al., 2015). 
However, it is not known how this would translate to ADB-CHMINACA despite structural similarity.  
Inter-individual genetic variability in metabolising enzymes 
No information specifically for ADB-CHMINACA has been identified.  
Interactions with other substances and other interactions 
No studies were identified that have examined the interaction of ADB-CHMINACA with other substances, 
including medicinal products. 
Effects on ability to drive and operate machines 
No studies of the effects of ADB-CHMINACA on the ability to drive and operate machines have been 
performed. However, it is has been reported that intoxications elicited by a variety of synthetic 
cannabinoids, including ADB-CHMINACA, significantly impair the mental and physical ability that is 
required to drive and operate machines (Section D1.2) (See also Capron, 2016; Kaneko, 2017; Karinen et 
al., 2015; Musshoff et al., 2014; Peterson and Couper, 2015). 
A3. Psychological and behavioural effects 
While there is limited data, the psychological and behavioural effects of ADB-CHMINACA appear to share 
some similarities with cannabis, THC, and other synthetic cannabinoids (e.g. Griffiths and Griffin, 2016; 
Peterson and Couper, 2015; See also Section D). This includes: relaxation, euphoria, lethargy, confusion, 
anxiety, fear, distorted perception of time, depersonalisation, hallucinations, paranoid inclusions, as well 
as dry mouth, bloodshot eyes, tachycardia, nausea, vomiting and impaired motor performance. These 
effects appear to be much more pronounced and severe when compared to cannabis (Ford et al., 2017; 
Zaurova et al., 2016). In addition, psychotic episodes, as well as aggressive and violent behaviour, have 
also been reported. (See also Section D1 and Section D3.4.) 
A4. Legitimate uses of the product  
ADB-CHMINACA is used as an analytical reference material in clinical and forensic case 
work/investigations as well as scientific research. There is currently no information that suggests ADB-
CHMINACA is used for other legitimate purposes. 
There are no reported uses of ADB-CHMINACA as a component in industrial, cosmetic or agricultural 
products. In addition, a search of the Registration, Evaluation, Authorisation and Restriction of Chemicals 
(REACH) registered substances database hosted by the European Chemicals Agency (ECHA) using the 
CAS Registry Number returned no results. 
There is no marketing authorisation (existing, on-going or suspended) for ADB-CHMINACA neither in the 
European Union nor in the Member States that responded to the request for information from the 
European Medicines Agency, which was undertaken as part of the Joint Report process (EMCDDA, 
2017c). 
There is no information to suggest that ADB-CHMINACA is currently used in the manufacture of a 
medicinal product in the European Union. However, in the absence of a database on the synthetic routes 
of all medicinal products it is not possible to confirm whether or not ADB-CHMINACA is currently used in 
the manufacture of a medicinal product.  
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Section B. Dependence and abuse potential 
B1. Animal data  
No studies were identified that have investigated the dependence and/or abuse potential of ADB-
CHMINACA in animal models.  
B2. Human data  
No studies were identified that have investigated the dependence and/or abuse potential of ADB-
CHMINACA in humans. However, it has been suggested that consumption of synthetic cannabinoids can 
produce tolerance and withdrawal symptoms when use is abruptly discontinued following a regular use 
(Cooper, 2016, Macfarlane and Christie, 2015, Van Hout and Hearne, 2017).  
Section C. Prevalence of use 
Information from seizures, collected and biological samples 
ADB-CHMINACA was formally notified on 24 September 2014 by the EMCDDA on behalf of the 
Hungarian National Focal Point, in accordance with Article 4 of the Council Decision. The Reporting Form 
details a seizure of 2.07 grams of light brown powder that was seized in August 2014 by Hungarian Police 
in Hajós. The identification and analytical characterisation was based on GC-MS, FT-IR and NMR 
analysis. 
Since then, a total of 17 Member States (Belgium, Croatia, Estonia, Finland, France, Germany, Greece, 
Hungary, Latvia, Lithuania, the Netherlands, Poland, Romania, Slovenia, Spain, Sweden and the United 
Kingdom), Turkey and Norway have reported detections of ADB-CHMINACA (EMCDDA, 2017c). 
Detections of ADB-CHMINACA may be under-reported since the substance is not routinely screened for. 
Three Member States (Austria, Slovenia and Sweden) reported that ADB-CHMINACA is part of routine 
screening in some (but not all) of their laboratories. 
Information from seizures 
A total of 19 countries reported seizures (37) of ADB-CHMINACA to the EMCDDA and/or Europol (38).  
Information reported to the EMCDDA and Europol indicates that 3794 seizures of ADB-CHMINACA have 
been reported by: Belgium (16), Croatia (2), Estonia (2), Finland (10), France (3), Germany (2), Greece 
(1), Hungary (75), Latvia (33), Lithuania (1), the Netherlands (1), Norway (2), Poland (233), Romania (1), 
Slovenia (1), Spain (1), Sweden (83), Turkey (3162) and the United Kingdom (165).  
The majority of the seizures comprise police and customs cases, with additional seizures taking place in 
custodial settings.  
                                                     
(37) Many  relate to individual case-level data, however, some data provided to the EMCDDA are aggregated at the country 
level. Data is drawn from the Joint Report Questionnaires and data provided in the bi-annual data gathering (EU EWS progress and 
final reports) and from individual Reporting forms submitted on an ad hoc basis. 
(38) The United Kingdom reported additional seizures of ADB-CHMINACA after the production of the Joint Report. 
19 
The most commonly seized physical forms were herbal (plant) materials and powders. A small number of 
seizures of blotters and other physical forms were also reported. 
Physical forms seized included: herbal material (485 seizures; amounting to a total weight of 11 kg), 
powders (76; 9.8 grams) and blotters (41; 25.35 grams and 2 blotters). Other physical forms were 
encountered in 22 of the cases (258.8 grams). 
No quantitative information on the purity of ADB-CHMINACA in seized samples was provided to the 
EMCDDA. 
Herbal material 
485 seizures of ADB-CHMINACA in herbal material were reported by 13 countries: Croatia, Estonia, 
Germany, Greece, Hungary, Latvia, Lithuania, Norway, Poland, Romania, Slovenia, Sweden and the 
United Kingdom, amounting to nearly 11 kg seized.  
Turkey reported around 3160 seizures of herbal material amounting to almost 128 kg which have not 
been included in the total count (39).  
The largest single seizure of ADB-CHMINACA in herbal material was reported by Germany; 1.66 kg of a 
mixture containing ADB-CHMINACA, 5F-AMB-PICA, EMB-FUBINACA, 5F-APP-PINACA, THC and 
cannabidiol.  
Greece reported a seizure of nine bags of herbal material, found to contain just over 1 kg of ADB-
CHMINACA mixed with 5F-AMB. The seizure was made during a raid on a tobacco store in Drama, 
where a number of products containing other synthetic cannabinoids were seized.  
In just over 30% of all cases involving herbal material, ADB-CHMINACA was often found mixed with other 
synthetic cannabinoids. 
Powders 
A total of 76 seizures of powders were reported by 10 countries: Belgium, Finland, France, Hungary, 
Latvia, the Netherlands, Poland, Spain, Sweden and Turkey, amounting to a total of 9.8 kg.  
In just over 90% of all cases involving powders, ADB-CHMINACA was the only substance detected. 
The largest single seizure of ADB-CHMINACA in powder form was 3 kg that was reported by Belgium. 
The consignment was seized by customs. It originated in China and was in transit to Austria and 
Romania.  
Turkey reported 2 large seizures of powders:  
 1.84 kg, containing ADB-CHMINACA, FUBIMINA, FUB-AKB, AMB-FUBINACA and NEP;  
 1 kg, containing ADB-CHMINACA mixed with THC, cannabinol and cannabidiol.  
                                                     
(39) Minimum estimate provided by the Turkish national focal point for 2016.  
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Blotters 
Seizures of blotters containing ADB-CHMINACA were reported by Poland (40 cases; 25.35 g) and 
Sweden (1 case; 2 blotters).  
Other physical forms 
Poland reported 19 seizures of   containing ADB-CHMINACA mixed with either 
caffeine (14 cases) or 5F-AKB48 (5), amounting to a total of over 235 g of substance.  
One seizure of a  containing ADB-CHMINACA mixed with MDMB-CHMICA was reported by Estonia 
(13.4 g); one case of a  containing ADB-CHMINACA, AB-FUBINACA, 5F-ADB-PINACA and FUB-
APINACA was reported by Norway (9.7 g) and one seizure of a -like  was reported by 
Finland (0.7 g). 
Information from collected samples 
Two collected samples of ADB-CHMINACA were reported to the EMCDDA by:  
 Slovenia, 5 g of white powder purchased online as -  from China, and; 
 Germany, ADB-CHMINACA identified as one of many substances in a number of powder 
samples collected from a scene of a death. 
Information from biological samples 
Serious adverse events (deaths and acute intoxications) with confirmed exposure to ADB-CHMINACA 
from biological samples are discussed in Section D. 
Additionally, a total of 28 analytically confirmed detections of ADB-CHMINACA in biological samples were 
reported by two Member States (40). Briefly these were:  
 22 cases related to drug abuse (consumption), intoxication or non-fatal intoxication, with no 
further details provided, Hungary (16 cases), Poland (6).  
 6 cases related to persons suspected of driving under the influence of drugs, all reported by 
Hungary.  
Availability, supply, price 
Information on production 
No information was received in relation to the production of ADB-CHMINACA. 
Information on trafficking 
                                                     
(40) Turkey reported 181 biological samples (blood, hair and urine) which may contain duplicates and therefore have not been 
included in the total count. 
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Information related to trafficking routes is limited. In cases reported to the EMCDDA, China was indicated 
as a source country in a customs seizure made in Belgium and collected sample reported by Slovenia. In 
addition, in two cases that were reported to Europol, one involved a courier seizure in Estonia that 
reportedly originated in Russia, and the second involved the interception of a postal package intercepted 
by customs in Bulgaria that arrived from Spain. 
Availability from Internet vendors 
The available data suggests that ADB-CHMINACA is sold openly online under its own name as powder 
and in herbal smoking mixtures (where the ingredients/composition is sometimes not stated). A structured 
search of online vendors on the surface web by the EMCDDA (41) found that the substance is available 
online in small and wholesale amounts as a   and as   a common 
reference to -  type products containing synthetic cannabinoids.  
On the websites identified, ADB-CHMINACA powders were available in amounts ranging from 1 gram to 
3 kg. Prices varied according to the amounts on sale and ranged from EUR 1.43 per gram to EUR 42.5 
per gram.  
The availability of ADB-CHMINACA on the darknet is not currently known. 
Prevalence of use  
No studies were identified that have investigated the prevalence of use of ADB-CHMINACA in the general 
population.  
Similar to other synthetic cannabinoids, ADB-CHMINACA is often sold and used as a  substitute for 
cannabis, typically as herbal smoking mixtures (EMCDDA, 2009; EMCDDA, 2017a). The composition of 
these products varies over time, with substances being changed in response to, or, in anticipation of, the 
introduction of control measures. This may have implications on the availability of ADB-CHMINACA and 
its prevalence of use. Overall, the available information does not suggest widespread use of the 
substance. 
Because of the variability in the composition of smoking mixtures, and the fact that the ingredients are not 
typically disclosed, most users will be unaware that they are using ADB-CHMINACA. As a result, the 
prevalence of use of ADB-CHMINACA should be considered in the wider context of the prevalence of use 
of herbal smoking mixtures, commonly referred to as  
The use of -like products has been studied in some European countries in general population 
surveys or in specific populations such as students,  and/or internet users. The results of these 
surveys are not comparable as they use different methodology and samples but overall they indicate 
generally low prevalence levels in these groups (EMCDDA, 2017a). 
There is evidence that in some groups, such as high risk drug users and other marginalised groups, the 
prevalence of use of synthetic cannabinoids, particularly as smoking mixtures, may be higher. This 
                                                     
(41) The search for online vendors of ADB-CHMINACA on the surface web was performed in October 2017. The search identified 5 
vendors that appeared to be based in, and/or claim to have presence in China (n=2; 1 of which in Hong Kong), Hungary (n=1) and 
Sweden (n=1); the remaining website did not list a location. Three websites listed quantities and prices for ADB-CHMINACA. The 
remaining sites only provided prices on request. 
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includes individuals who are subject to drug testing (such as people in drug treatment, prisoners, and 
drivers) because some drug tests/screens will be unable to detect synthetic cannabinoids. In addition 
some vulnerable populations, such as the homeless and prisoners, specifically seek out synthetic 
cannabinoids because they have a reputation for causing profound intoxication, they can be cheap and 
are easy to smuggle (EMCDDA, 2017a; Blackman and Bradley, 2017; HMIP, 2015; Ralphs et al., 2017; 
User Voice, 2016). 
Section D. Health risks 
D1. Acute health effects 
D1.1. Animal data 
Data on the acute toxicity, abuse liability or dependence producing potential of ADB-CHMINACA could 
not be identified.  
D1.2. Human data 
No clinical studies were identified that have examined the acute health effects of ADB-CHMINACA and/or 
its metabolites in humans. Data from serious adverse events associated with ADB-CHMINACA are 
discussed below. In general, the acute health risks associated with ADB-CHMINACA appear to be similar 
to those found with other synthetic cannabinoids. 
As synthetic cannabinoids activate the CB1 receptor in a similar way to THC, their effects appear to have 
some similarities with cannabis (Auwärter et al., 2009). This includes: relaxation, euphoria, lethargy, 
confusion, anxiety, fear, distorted perception of time, depersonalisation, hallucinations, paranoid 
inclusions, as well as dry mouth, bloodshot eyes, tachycardia, nausea, vomiting and impaired motor 
performance. These effects appear to be much more pronounced and severe when compared to 
cannabis (Ford et al., 2017; Winstock et al., 2013; Zaurova et al., 2016). 
Severe and fatal poisoning also appears to be more common with synthetic cannabinoids as compared to 
cannabis. This can include severe cardiovascular toxicity (including sudden death), rapid loss of 
consciousness/coma, respiratory depression, seizures and convulsions, hyperemesis, delirium, agitation, 
psychosis, and aggressive and violent behaviour (Adams et al., 2017; Brenneman et al., 2016; Capron, 
2016; Ford et al., 2017, Hermanns-Clausen et al., 2013; EMCDDA, 2017c, EMCDDA, 2017d, EMCDDA, 
2017e; EMCDDA, 2017g; Kasper et al., 2015; Pap, 2016; Schwartz et al., 2015; Shevyrin et al., 2015; 
Springer et al., 2016; Tait et al., 2016; Trecki et al., 2015; Tyndall et al., 2015; Waugh et al., 2016; 
Winstock et al., 2013; Zaurova et al., 2016). (See Section D3.4.) 
In addition, some of the features of poisoning particularly loss of consciousness, respiratory depression, 
and behavioural effects may place users at additional risks, such as choking on/aspirating vomit, 
drowning, falling, hypothermia as a result of falling unconscious outside in cold weather, and self-inflicted 
violence/injury (EMCDDA, 2017g; Tait et al., 2016; Yeter, 2017). The aggressive and violent behaviours 
reported with synthetic cannabinoids may also place others at risk of injury. 
Overall, poisoning with synthetic cannabinoids may be made worse when other drugs, especially central 
nervous system depressants (such as alcohol, opioids, and sedative/hypnotics), are used at the same 
time.  
There is no approved antidote to poisoning caused by synthetic cannabinoids. 
Acute intoxications reported by the Member States 
23 
A total of 3 acute intoxications with confirmed exposure to ADB-CHMINACA were reported by the United 
Kingdom (42). The cases occurred during 2016. In 1 case, no other substances were detected. In the 
remaining 2 cases, another synthetic cannabinoid was detected. All the cases included clinical features of 
poisoning similar to those reported for other synthetic cannabinoids. 
Acute intoxications identified from other sources 
Table 4 provides a summary of non-fatal intoxications and cases of suspected driving under the influence 
of drugs identified in the literature involving confirmed exposure to ADB-CHMINACA. Where reported, the 
range of ADB-CHMINACA concentration in serum ranged from 0.22 to 31 ng/mL. The clinical features of 
poisoning were similar to those reported for other synthetic cannabinoids.
                                                     
(42) In addition, Germany reported 8 acute intoxications with possible exposure to ADB-CHMINACA and Sweden reported 2 acute 
intoxications with suspected exposure to ADB-CHMINACA. These cases are not discussed further in this report. 
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 Deaths reported by the Member States 
Deaths 
A total of 13 deaths were reported by 3 Member States: Germany (6), Sweden (5) and Hungary (2). In all 
cases, exposure to ADB-CHMINACA was analytically confirmed from post-mortem samples.  
The German deaths occurred between January 2015 and September 2016. Those in Hungary occurred in 
2016 and October 2014. Four of the five deaths in Sweden occurred between February and July 2015, 
with the remainder occurring in October 2016. 
Demographic data were available for all but one death and involved only males. The mean age was 28 
years (median 28) and ranged from 17 to 38 years. 
Circumstances and cause of death 
There was a lack of information regarding any symptoms experienced by the deceased prior to death in 
the majority of cases. Where described, the deceased had been sleeping, had vomited or had become 
unconscious. Where information was known, in the majority of instances the individuals were found dead, 
predominantly in a home environment (either their own or a  Consequently, it was not possible to 
identify or evaluate ante-mortem symptoms (especially in relation to acute intoxication) in these cases. 
A cause of death was reported in all but one case, and, in at least 9 deaths, ADB-CHMINACA was either 
the cause of death or is likely to have contributed to death (even in presence of other substances); other 
substances were detected in 11 cases. ADB-CHMINACA was the only drug present in 1 death where 
additional toxicological information was known. 
ADB-CHMINACA was quantified in 12 cases. Post-mortem blood concentrations between 0.7 and 16 
ng/mL (median 1.1 ng/mL) and between 5 and 30 ng/g blood were recorded (median 10 ng/g blood). With 
ng/g being approximately equivalent to ng/mL, an inclusive range of 0.7 to 30 and median of 5.9 ng/mL in 
blood (~ng/g) across all 12 cases. Due to the toxicity of potent synthetic cannabinoids, a post-mortem 
blood concentration cannot necessarily be used to determine a  concentration. In the majority of 
circumstances involving synthetic cannabinoids, the mere presence of the drug is of significance whether 
concentration has been determined or not, especially in situations of poly-drug use and the varying 
circumstances in which they are used. 
A range of other substances were detected in the deaths, including: alcohol, cannabinoids, cocaine, 
antidepressants, antipsychotics, synthetic cathinones, diphenidines, opioids (buprenorphine and 
methadone) and benzodiazepines. Other synthetic cannabinoid receptor agonists were detected in 3 of 
the deaths; 5F-AKB-48, AKB-48, 5F-PB-22, FUB-AKB48 (FUB-APINACA), FUB-AMB, AB-CHMINACA. In 
one of these cases, 5 other synthetic cannabinoids were detected in addition to ADB-CHMINACA. 
Overall, whilst other substances may have contributed some toxicity, the potent nature of ADB-
CHMINACA means the primary toxic contribution could be attributed to the drug and death may not have 
occurred if ADB-CHMINACA had not been used. However, in the 3 cases where multiple synthetic 
cannabinoids were present, it is not possible or appropriate to identify ADB-CHMINACA as the primary 
synthetic cannabinoid that may have produced toxicity but a synergistic effect is likely nonetheless. 
Sufficient case data were available in all 13 deaths and an assessment of the toxicological significance 
score (TSS) (Elliott, Sedefov, & Evans-Brown, 2017) incorporating the above considerations in the 
deaths, showed that ADB-CHMINACA had a TSS value of 3 (high) in all 13 deaths (where it was cited as 
the cause of death or is likely to have contributed to death). 
  
37 
Deaths identified from other sources 
Table 5 provides a summary of deaths identified in the literature involving confirmed exposure to ADB-
CHMINACA. The majority of cases occurred in United States in the period towards the end of 2014 and 
beginning of 2015. In cases where the demographic of subjects was provided, young male patients were 
involved (reported ages: 18, 20, and 30). In two cases the blood concentration of ADB-CHMINACA was 
reported (6.05 ng/ml and 2.7 ng/mL) and in once case ADB-CHMINACA was quantified in urine (229 
pg/mL).
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D2. Chronic health effects 
D2.1. Animal data 
No studies were identified that have investigated the chronic health effects of ADB-CHMINACA in 
animals. 
D2.2. Human data 
No studies were identified that have investigated the chronic health effects of ADB-CHMINACA in 
humans. 
D3. Factors affecting public health risks 
D3.1. Availability and quantity of the new psychoactive substance on the market 
ADB-CHMINACA is sold on the surface web as a powder and in -  type products such as herbal 
smoking mixtures. The substance is available in small and wholesale amounts. Herbal smoking mixtures 
do not commonly state the presence of synthetic cannabinoids. As a result, many users will not be aware 
that they are using such substances.  
D3.2. Availability of the information, degree of knowledge and perceptions amongst users 
concerning the psychoactive substance and its effects 
The availability of information, degree of knowledge and perceptions amongst users concerning ADB-
CHMINACA and its effects are limited. There is considerable variability both within and between different 
batches of synthetic cannabinoid products, in terms of both the substances and the amount present. For 
that reason, most individuals will be unaware that they are using ADB-CHMINACA. 
Unknown to users, synthetic cannabinoids have also been sold as ecstasy/MDMA and other illicit drugs. 
In some cases, this has led to severe poisoning (Allibe et al., 2016; Brenneman et al., 2016; Pap, 2016). 
Opioids (such as U-47,700 and furanylfentanyl) have also been identified in smoking mixtures/plant 
material. Users will be unaware of this, and the use of such opioid-containing products could pose a risk 
of life-threatening respiratory depression. This risk will be especially high in individuals with no tolerance 
to opioids (Coopman et al., 2017; EMCDDA, 2017h). 
D3.3. Characteristics and behaviour of users  
No studies were identified that have examined the characteristics and behaviour of users of ADB-
CHMINACA.  
Synthetic cannabinoids are sold and used as a  replacement for cannabis (EMCDDA, 2009; 
EMCDDA, 2017a). In addition some users specifically seek out synthetic cannabinoids because they 
have a reputation for causing profound intoxication,  they can be cheap and are easy to smuggle. In most 
cases they are smoked using a cigarette of plant material that has been mixed with one or more of the 
cannabinoids. Because these products rarely state the ingredients, most users will be unaware that they 
are using synthetic cannabinoids. 
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People who use synthetic cannabinoids may include recreational users (including cannabis users), high-
risk drug users, and groups who experiment with the substances (such as psychonauts). They may also 
include individuals who are subject to drug testing (such as people in drug treatment, prisoners, and 
drivers) because some drug tests/screens will be unable to detect some of the cannabinoids (especially 
those that are relatively new to the drug market). In the past few years, synthetic cannabinoids have 
become increasingly used by vulnerable groups (such as the homeless and prisoners). 
D3.4. Nature and extent of health consequences 
The limited information available on the pharmacology, dependence and abuse potential, and acute 
health effects of ADB-CHMINACA have been discussed above (Section A2, Section B, Section D1 and 
Section D2).  
Compared to cannabis, more pronounced effects as well as severe and fatal poisoning appear to be more 
common with synthetic cannabinoids (EMCDDA, 2017c; EMCDDA, 2017d, EMCDDA, 2017e, EMCDDA, 
2017f, EMCDDA, 2017g; Tait et al., 2016; Waugh et al., 2016; Winstock et al., 2013; Zaurova et al., 
2016). The reasons for this are poorly understood, but at least two factors are likely to be important: the 
high potency of the substances and the unintentionally high doses that users are exposed to. 
Firstly, studies have found that many of the cannabinoids, including ADB-CHMINACA, which are sold on 
the drug market, are much more potent and active, typically behaving as full agonists, as compared to 
THC. This means that even at very small doses they can activate the CB1 receptor much more strongly 
than THC (Banister et al., 2016; Ford et al., 2017; Reggio, 2009; Tai and Fantegrossi, 2017).  
Secondly, the process for mixing the synthetic cannabinoids with the herbal/plant material (which are the 
most common way of using these substances) can lead to dangerous amounts of the substances in the 
products. This is because producers have to guess the amount of cannabinoids(s) to add, while the 
mixing process makes it difficult to dilute the substances sufficiently and distribute them consistently 
throughout the plant material. This can result both in products that contain toxic amounts of the 
substances in general (Ernst et al., 2017; Frinculescu et al., 2016; Langer et al., 2014: Langer et al., 
2016), as well as products where the cannabinoids are clumped together forming highly concentrated 
pockets within the plant material (Frinculescu et al., 2016; Moosmann et al., 2015; Schäper et al., 2016). 
These issues are made worse as the products are smoked (and, to a lesser degree, vaped) allowing the 
substances to be rapidly absorbed into the systemic circulation (bloodstream) and to reach the brain. 
The combination of these two factors makes it difficult for users to control the dose that they are exposed 
to and can lead them to rapidly administer a toxic dose unintentionally. Accounts from patients and 
people who witness poisonings suggest that in some cases a small number of puffs from a cigarette have 
been sufficient to cause severe and fatal acute poisoning.  
These two factors are also responsible for outbreaks of mass poisonings caused by smoking mixtures, 
which have ranged in size from four or five victims to over 800. Mass poisonings can overwhelm 
emergency responders and other local healthcare systems. Many of the outbreaks that have been 
reported so far are from the United States, but they have also occurred in Russia and Europe (Adams et 
al., 2017; Kasper et al., 2015; Schwartz et al., 2015; Shevyrin et al., 2015; Springer et al., 2016; Trecki et 
al., 2015; Tyndall et al., 2015). Such types of outbreaks have been reported for ADB-CHMINACA (DHSL, 
2014; Trecki et al., 2015). 
Driving while under the influence of synthetic cannabinoids places users and others at risk of injury 
(Capron, 2016; Kaneko, 2017; Karinen et al., 2015; Musshoff et al., 2014; Peterson and Couper, 2015). In 
a recent case series of 36 drivers suspected of driving under the influence of drugs in Washington, United 
States, where 5F-MDMB-PINACA was the predominate psychoactive substance identified, 50% of the 
drivers were found unconscious and 28% has been involved in collisions with single/multiple cars 
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(Capron, 2016). Similarly, the operation of machinery while under the influence of synthetic cannabinoids 
may place the user and others at risk of injury. 
D3.5. Long-term consequences of use 
While there is limited data for ADB-CHMINACA, the long-term consequences of use might share 
similarities to cannabis and other synthetic cannabinoids. This may include dependence. 
D3.6. Conditions under which the new psychoactive substance is obtained and used, including 
context-related effects and risks 
There is limited data on the conditions which ADB-CHMINACA is obtained and used. 
Sources appear to include internet retailers, physical shops, friends and other acquaintances, and street-
level drug dealers (Section D3.1). In addition, most users will be unaware that they have sourced and 
used ADB-CHMINACA (Section C and Section D1.2.1). The available data suggests that ADB-
CHMINACA is used in the same environments as cannabis, including the home, and, to a lesser extent, 
in recreational settings.  
Section E. Social Risks 
The available data suggests that the acute behavioural effects of ADB-CHMINACA bear some similarities 
to cannabis but are more pronounced and severe. 
In addition, and, of particular note, is that in some settings, synthetic cannabinoids are increasingly used 
by high risk drug users and other vulnerable groups, such as the homeless and prisoners. In at least 
some cases, these users are specifically seeking out synthetic cannabinoids because the substances 
have developed a reputation for causing profound intoxication, they can be cheap and are easy to 
smuggle. Reports suggest that this has exacerbated existing health and social problems for these 
vulnerable groups, as well as creating new ones.  
E1. Individual social risks 
There is no information on whether the use of ADB-CHMINACA causes individual social risks; however, 
they may have some similarities with those associated with other synthetic cannabinoids. These may 
impact on education or career, family or other personal and social relationships and may result in 
marginalisation. 
E2. Possible effects on direct social environment  
While there is no specific information on the possible effects of ADB-CHMINACA on the direct social 
environment, the behavioural effects of synthetic cannabinoids include reports of aggressive and violent 
behaviour. This may place users and others at risk of injury. 
E3. Possible effects on society as a whole 
There is no specific information on the possible effects of ADB-CHMINACA on society as a whole.  
E4. Economic costs 
There are no data on the effects of ADB-CHMINACA in respect to its health and social costs.  
E5. Possible effects related to the cultural context, for example marginalisation 
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There is no specific data on the possible effects of ADB-CHMINACA related to the cultural context.  
Of particular note is that synthetic cannabinoids are increasingly used by vulnerable groups, such as the 
homeless and prisoners. Reports suggest that this has caused new health and social problems as well as 
exacerbated existing ones for these groups. For example, in prisons, alongside the adverse health 
effects, the market in synthetic cannabinoids has been linked to an increase in aggression, violence, 
bullying, and debt. In some cases this has caused a serious threat to the overall safety and security of the 
prison environment (Blackman and Bradley, 2017; HMIP, 2015; Ralphs et al., 2017; User Voice, 2016). 
E6. Possible appeal of the new psychoactive substance to specific population groups within the 
general population 
While no specific examples are available on the possible appeal of ADB-CHMINACA to specific user 
groups, it is reasonable to assume ADB-CHMINACA may be sought by those looking for  
substitutes for cannabis. This includes individuals subject to drug testing (such as drivers, prisoners, and 
those in drug treatment). 
In addition, and, of particular note, is that synthetic cannabinoids are increasingly used by high risk drug 
users and other vulnerable groups, such as the homeless and prisoners. In at least some cases, these 
users are specifically seeking out synthetic cannabinoids because they have developed a reputation for 
causing profound intoxication, they can be cheap and are easy to smuggle Reports suggest that this has 
exacerbated existing health and social problems as well as creating new ones for these groups. For 
example, in prisons, alongside the adverse health effects, the market in synthetic cannabinoids has been 
linked to an increase in aggression, violence, bullying, and debt. In some cases this has caused a serious 
threat to the overall safety and security of the prison environment (Blackman et al., 2017; HMIP, 2015; 
Ralphs et al., 2017; User Voice, 2016). 
Section F. Involvement of organised crime 
F1. Evidence that criminal groups are systematically involved in production, trafficking and 
distribution for financial gain 
There is no specific information to suggest the involvement of organised crime or established criminal 
groups in the manufacture, distribution and supply of ADB-CHMINACA. 
In the cases where the origin of the seizures reported to Europol was known, the country of origin 
indicated was: Spain (1) and Russia (1). Bulgaria reported 1 seizure which was en-route from Spain. 
Bulgaria also reported an additional seizure in 2016 which was reported to have been intended for 
distribution within the country and was offered for sale via the internet. Estonia reported 1 seizure of ADB-
CHMINACA from a courier, which was en-route from Russia.  
In the cases where the origin of seizures reported to the EMCDDA was known, the country of origin 
indicated was China (1). Belgian customs reported the largest single seizure of ADB-CHMINACA in 
powder form, which amounted to 3 kg. The seizure was en-route from China and destined for Austria and 
Romania. 
F2. Impact on the production, trafficking and distribution of other substances, including existing 
psychoactive substances as well as new psychoactive substances 
No information was reported nor identified concerning the impact of ADB-CHMINACA on the production, 
trafficking and distribution of other substances, including existing psychoactive substances as well as new 
psychoactive substances. 
45 
F3. Evidence of the same groups of people being involved in different types of crime 
No information was reported nor identified concerning evidence of the same groups of people being 
involved in different types of crime related to the availability of ADB-CHMINACA. 
F4. Impact of violence from criminal groups on society as a whole or on social groups or local 
communities (public order and safety) 
No information was reported nor identified concerning incidents of violence related to the availability of 
ADB-CHMINACA.  
F5. Evidence of money laundering practices, or impact of organised crime on other 
socioeconomic factors in society 
No information was reported nor identified concerning evidence of money laundering practices, or impact 
of organised crime on other socioeconomic factors in society related to the availability of ADB-
CHMINACA. 
F6. Economic costs and consequences (evasion of taxes or duties, costs to the judicial system)  
No information was reported nor identified concerning the economic costs and consequences related to 
the availability of ADB-CHMINACA. 
F7. Use of violence between or within criminal groups 
No information was reported nor identified concerning the use of violence between or within criminal 
groups related to the availability of ADB-CHMINACA. 
F8. Evidence of strategies to prevent prosecution, for example through corruption or intimidation 
No information was reported nor identified concerning evidence of strategies to prevent prosecution 
related to the availability of ADB-CHMINACA.  
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